PK/PD analyses of circulating tumor DNA (ctDNA) in patients with metastatic colorectal cancer (mCRC) treated with telisotuzumab adizutecan (ABBV-400). This is an ASCO Meeting Abstract from the 2025 ...

Oncologists in 2023 are experiencing higher rates of burnout compared with a decade ago. System-based interventions to reduce burnout are necessary to maintaining an adequate workforce to provide care ...

Burnout in oncologists has been increasing, especially after the COVID-19 pandemic. This is concerning because burnout can have both personal and professional repercussions, as well as a negative ...

Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...

Delta-Radiomics Using Machine Learning Classifiers With Auxiliary Data Sets to Predict Disease Progression During Magnetic Resonance-Guided Radiotherapy in Adrenal Metastases This study was approved ...

Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers BV combined with Len + R demonstrated significant improvements in overall survival (OS; 37% reduced risk of ...

The improvement in measures of well-being over the past decade illustrates that progress is possible and should encourage the cancer care community to continue efforts to optimize oncology training.

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial A cost-utility analysis was performed ...

What Are the Real Pros of Real-Time PROs (Patient-Reported Outcomes)? The following represents disclosure information provided by the author of this manuscript. All relationships are considered ...

Genomic analysis of paired primary and metastatic pancreatic ductal adenocarcinoma tumors.

The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The ...

Exploration of novel biomarkers and novel therapies for immune checkpoint inhibitors (ICIs) in genetic variants of esophageal squamous cell carcinoma (ESCC): A study of 1,059 Japanese cases.